期刊
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
卷 5, 期 10, 页码 -出版社
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a021196
关键词
-
资金
- Mallinckrodt Scholar Award
- Searle Scholar Award
- National Institutes of Health Director's New Innovator Award [1DP2OD008614-01]
- Vallee Foundation Young Investigator Award
- Whitehead Scholar Award
- Duke University Center for AIDS Research [5P30 AI064518]
Host-directed therapies are a relatively new and promising approach to treatment of tuberculosis. Modulation of specific host immune pathways, including those that impact inflammation and immunopathology, can limit mycobacterial infection and pathology, both in cell culture and in animal models. This review explores a range of host pathways and drugs, some already approved for clinical use that have the potential to provide new adjunctive therapies for tuberculosis. Drugs targeting host processes may largely avoid the development of bacterial antibiotic resistance, a major public health concern for tuberculosis. However, these drugs may also have generally increased risk for side effects on the host. Understanding the specific mechanisms by which these drugs act and the relationship of these mechanisms to Mycobacterium tuberculosis pathogenesis will be critical in selecting appropriate host-directed therapy. Overall, these host-directed compounds provide a novel strategy for anti-tuberculosis therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据